ArticleThe Journal of clinical investigation2009
Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects.
Article in The Journal of clinical investigation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 63 citations in OpenAlex.
- Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma.Journal for immunotherapy of cancer · 2017Trial
- Melanoma: Pathogenesis and Targeted Therapy.MedComm · 2026Review
- Targeting pattern recognition receptors for cancer therapy: Mechanisms and strategies.Acta pharmaceutica Sinica. B · 2025Review
- Personalized Cancer Vaccines in Combination Therapies: Current Status and Future Prospects.Asian Pacific journal of cancer prevention : APJCP · 2025Review
- Intrinsic RIG-I restrains STAT5 activation to modulate antitumor activity of CD8+ T cells.The Journal of clinical investigation · 2023Article
- Repositioning of Antiparasitic Drugs for Tumor Treatment.Frontiers in oncology · 2021Review
- Blocking drug-induced autophagy with chloroquine in HCT-116 colon cancer cells enhances DC maturation and T cell responses induced by tumor cell lysate.International immunopharmacology · 2020Article
- Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression.International journal of molecular sciences · 2019Article
- Knockdown of IGF-1R Triggers Viral RNA Sensor MDA5- and RIG-I-Mediated Mitochondrial Apoptosis in Colonic Cancer Cells.Molecular therapy. Nucleic acids · 2019Article
- Next Generation Cancer Vaccines-Make It Personal!Vaccines · 2018Review
- Combined roles of ATP and small hairpin RNA in the activation of RIG-I revealed by solution-based analysis.Nucleic acids research · 2018Article
- Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations.Human vaccines & immunotherapeutics · 2017Review
- Vaccine adjuvants as potential cancer immunotherapeutics.International immunology · 2016Review
- Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer.Journal of virology · 2014Article
- Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer.Molecular therapy oncolytics · 2014Review
- Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go.Frontiers in immunology · 2013Review
- Deciphering and reversing tumor immune suppression.Immunity · 2013Review
- Preexisting antitumor immunity augments the antitumor effects of chemotherapy.Cancer immunology, immunotherapy : CII · 2013Article
- A caspase-3 'death-switch' in colorectal cancer cells for induced and synchronous tumor apoptosis in vitro and in vivo facilitates the development of minimally invasive cell death biomarkers.Cell death & disease · 2013Article
- The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.Nature reviews. Drug discovery · 2013Review
Corrections and comments
- Comment on
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conventional chemotherapeutics may induce immunogenic cancer cell death or stimulate immune effectors via so-called off-target effects. The study by Besch et al. in this issue of the JCI now demonstrates that agents designed to stimulate the innate immune system by activating intracellular pattern recognition receptors can kill cancer cells in a direct, cell-autonomous fashion (see the related article beginning on page 2399). The authors show that ligation of viral RNA sensors, such as RIG-I or MDA-5, by viral RNA mimetics triggers mitochondrial apoptosis in human melanoma cells in an IFN-independent fashion. The data suggest that tumor cell killing and immunostimulation may synergize for optimal anticancer immunochemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.